How RNA therapeutics can be used to treat retinitis pigmentosa
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
List view / Grid view
Articles
Fighting HIV: could antibodies be the answer?
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
Immunosurveillance and the importance of CD4 T cells in developing cancer vaccines
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
The development of biomaterial-based vaccine platforms against viruses
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Drug Target Review Vaccine Development ebook 2021
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
Broad T-cell responses: designing a rhinovirus vaccine
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
A novel assay to reveal cyclic peptides with affinity to ubiquitin
Although macrocyclic peptides make for promising pharmaceutical candidates, screening for lead peptides has proved difficult for scientists. In a new study, researchers at the Technion-Israel Institute of Technology addressed these challenges by developing a novel high-throughput screening assay for cyclic peptides with affinity to the ubiquitin protein. Drug Target Review’s…
Synthesising very long-chain fatty acids to treat retinal conditions
A class of lipids – or fatty acids – found in the retina of the eye play an important role in maintaining vision. Victoria Rees, Deputy Editor of Drug Target Review, spoke with Dr Paul Bernstein from the Moran Eye Center at the University of Utah, US, to discover how…
COVID-19 drug targets and cell-based assays
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
Which CHO cell is the right CHO cell?
Dr Louis Boon offers guidance on how to select the best CHO cell for the upstream bioprocessing of biologics. He also explains how automation can aid monoclonality and why the most efficient approach during the development of biological drugs is to utilise an established cell line platform.
COVID-19 in Europe – one year on from the first case
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
Drug Target Review Assays ebook 2021
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.